| CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO (NCT03227328) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2017-08-02 |
| Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers (NCT05765357) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-07-16 |
| Metastatic Breast Cancer Treatment Planning (NCT03127332) | Carevive Systems, Inc. | 2017-07-01 |
| Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC (NCT03184090) | MedSIR | 2017-06-28 |
| Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide (NCT03139851) | Centre Leon Berard | 2017-06-27 |
| Understanding Value in Metastatic Breast Cancer (NCT03257917) | University of Alabama at Birmingham | 2017-06-13 |
| CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer (NCT05652569) | German Cancer Research Center | 2017-06-12 |
| PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer (NCT03166085) | Memorial Sloan Kettering Cancer Center | 2017-05-23 |
| ESR1 Mutations in Asian ER+ Metastatic Breast Cancer on Hormonal Therapy-based Treatments (NCT04212702) | National Taiwan University Hospital | 2017-05-22 |
| Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC (NCT03051672) | Dana-Farber Cancer Institute | 2017-05-22 |
| Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer (NCT02658084) | University of Miami | 2017-04-12 |
| "Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer (NCT03072992) | National Center of Oncology, Armenia | 2017-03-20 |
| Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer (NCT03442504) | Institut Cancerologie de l'Ouest | 2017-03-15 |
| Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET (NCT04992156) | Fudan University | 2017-03-15 |
| Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer (NCT03195192) | Side-Out Foundation | 2017-03-09 |
| Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast Cancer (NCT03151447) | Fudan University | 2017-03-06 |
| Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers (NCT03073473) | Cota Inc. | 2017-02-28 |
| Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer (NCT02687490) | Fudan University | 2017-02-24 |
| Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer (NCT02668666) | Oana Danciu, MD | 2017-02-01 |
| A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC) (NCT02611310) | Hoffmann-La Roche | 2017-01-19 |
| Plasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast Cancer (NCT03161834) | UNC Lineberger Comprehensive Cancer Center | 2017-01-13 |
| Palbociclib in Real World Practice (NCT03280303) | Pfizer | 2017-01-04 |
| Quality of Life and Psychological Vulnerability in Patients With RH+ Metastatic Breast Cancer (NCT03636776) | Institut Cancerologie de l'Ouest | 2016-12-29 |
| Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer (NCT05427617) | Hunan Cancer Hospital | 2016-12-01 |
| Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer (NCT03007992) | Johannes Gutenberg University Mainz | 2016-12-01 |
| Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer (NCT05079074) | Hunan Cancer Hospital | 2016-12-01 |
| Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer (NCT02980341) | Daiichi Sankyo Co., Ltd. | 2016-11-28 |
| Improving the Approach to and Management of the Older Metastatic Breast Cancer Patient (NCT03007641) | Fox Chase Cancer Center | 2016-11-01 |
| A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer (NCT02595762) | Hoffmann-La Roche | 2016-10-30 |
| Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor (NCT02738866) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2016-10-25 |
| An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer (NCT02939274) | Rogers Sciences Inc. | 2016-10-01 |
| A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy (NCT02924883) | Hoffmann-La Roche | 2016-09-26 |
| A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (NCT02747004) | Eli Lilly and Company | 2016-09-14 |
| Open-label Study of Safety, Tolerability and Pharmacokinetics of Multiple Doses of BI-CON-02 in Patients With HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab (NCT03062007) | Biointegrator LLC | 2016-09-01 |
| Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC) (NCT02753595) | Eisai Inc. | 2016-07-13 |
| Quell Opioid Reduction and Pain Relief in Patients With Cancer (NCT02809846) | Scripps Translational Science Institute | 2016-07-01 |
| A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC (NCT02592746) | Samsung Medical Center | 2016-06-01 |
| Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab (NCT02649686) | Canadian Cancer Trials Group | 2016-05-17 |
| Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer (NCT02719691) | University of Colorado, Denver | 2016-05-13 |
| Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer (NCT02802098) | Centro Nacional de Investigaciones Oncologicas CARLOS III | 2016-05-01 |
| Palliative and Oncology Care Model in Breast Cancer (NCT02730858) | Massachusetts General Hospital | 2016-05-01 |
| Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to the Bone: A Whole Body MRI Study (NCT03266744) | East and North Hertfordshire NHS Trust | 2016-04-21 |
| Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (NCT02657889) | Tesaro, Inc. | 2016-04-15 |
| Real-world Evidence Prospective Study on the Effect of Nab-paclitaxel Treatment on the Clinical Outcomes and HRQoL in Patients With MBC in Greece (NCT02626013) | Genesis Pharma S.A. | 2016-04-12 |
| Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer (NCT03057743) | Abramson Cancer Center at Penn Medicine | 2016-04-05 |
| Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients (NCT02829008) | Chinese Academy of Medical Sciences | 2016-04-01 |
| Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients (NCT02655952) | WntResearch AB | 2016-04-01 |
| Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer (NCT02650817) | Stemline Therapeutics, Inc. | 2016-04-01 |
| Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer (NCT02524951) | Northwell Health | 2016-04-01 |
| PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO) (NCT02723877) | PIQUR Therapeutics AG | 2016-03-28 |
| Evaluation Of CanADVICE+®M-Health System To Support Breast Cancer Patients Receiving Capecitabine (NCT02580396) | Royal Marsden NHS Foundation Trust | 2016-03-16 |
| ER Reactivation Therapy for Breast Cancer (NCT02188745) | Dartmouth-Hitchcock Medical Center | 2016-03-11 |
| A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature (NCT02505048) | UNICANCER | 2016-03-01 |
| ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer (NCT02632071) | Columbia University | 2016-03-01 |
| Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer (NCT02632045) | Melissa K Accordino | 2016-03-01 |
| Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients (NCT02642458) | University Hospital Tuebingen | 2016-03-01 |
| 2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer (NCT02624700) | Virginia Commonwealth University | 2016-01-28 |
| Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases (NCT02650752) | Memorial Sloan Kettering Cancer Center | 2016-01-06 |
| Clinical Utility of CTC Test in Medicare-Eligible Metastatic Breast Cancer Patients (NCT02111031) | Janssen Diagnostics, LLC | 2016-01-01 |
| Evaluate the Safety Profile and Ability of TW1025 Oral Solution to Decrease Fatigue (NCT02645175) | Meriyana Bio Inc. | 2016-01-01 |
| Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects (NCT02310464) | OBI Pharma, Inc | 2015-12-22 |
| A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy (NCT02536339) | Genentech, Inc. | 2015-12-16 |
| Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer (NCT02594371) | Athenex, Inc. | 2015-12-02 |
| Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer (NCT02651610) | Peregrine Pharmaceuticals | 2015-12-01 |
| Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate (NCT02581839) | Case Comprehensive Cancer Center | 2015-11-17 |
| [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer (NCT02608216) | University of Pennsylvania | 2015-11-01 |
| Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments (NCT02284581) | Consorzio Oncotech | 2015-11-01 |
| Platinum Rechallenge in Patients With Platinum-sensitive mTNBC (NCT02607215) | Fudan University | 2015-11-01 |
| A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer (NCT02384239) | University of California, San Francisco | 2015-10-19 |
| [18F]FES PET/CT in Endocrine Refractory Breast Cancer (NCT02409316) | University of Pennsylvania | 2015-10-15 |
| Thalidomide Plus Chemotherapy Versus Chemotherapy Alone for Advanced Breast Cancer (NCT02649101) | Zhejiang Cancer Hospital | 2015-10-01 |
| Physical Activity to Maintain Quality of Life and Physical Function in Women With Metastatic Breast Cancer: a Pilot Study (NCT02682836) | UNC Lineberger Comprehensive Cancer Center | 2015-10-01 |
| Brain Irradiation and Tremelimumab in Metastatic Breast Cancer (NCT02563925) | Memorial Sloan Kettering Cancer Center | 2015-09-18 |
| Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer (NCT02506556) | Peter MacCallum Cancer Centre, Australia | 2015-09-07 |
| Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer (NCT03507088) | Zhimin Shao | 2015-09-01 |
| Detect V / CHEVENDO (Chemo vs. Endo) (NCT02344472) | Prof. Wolfgang Janni | 2015-09-01 |
| Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer (NCT02544243) | Shandong Cancer Hospital and Institute | 2015-09-01 |
| A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway (NCT02544997) | Samsung Medical Center | 2015-09-01 |
| LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer (NCT02538471) | Weill Medical College of Cornell University | 2015-08-10 |
| Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer (NCT02491983) | MedSIR | 2015-08-01 |
| CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) (NCT02580448) | Innocrin Pharmaceutical | 2015-08-01 |
| A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer (NCT02370238) | Dompé Farmaceutici S.p.A | 2015-07-29 |
| A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer (NCT02423902) | Alaunos Therapeutics | 2015-07-18 |
| Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients (NCT02479230) | Joseph Baar, MD, PhD | 2015-07-17 |
| Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer (NCT02448420) | SOLTI Breast Cancer Research Group | 2015-07-01 |
| Metastatic Breast Cancer in Brazil: Characterization of Patients and Treatments (NCT02662868) | Latin American Cooperative Oncology Group | 2015-06-01 |
| Study of ESR1 Mutations in Metastatic Breast Cancer (NCT02473120) | Centre Henri Becquerel | 2015-06-01 |
| A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer (NCT02447328) | AstraZeneca | 2015-05-29 |
| Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor (NCT02444390) | UNICANCER | 2015-05-19 |
| Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC (NCT02436772) | SCRI Development Innovations, LLC | 2015-05-13 |
| Evolution of Resistance to Systemic Therapies in Patients With Breast Cancer (NCT02257775) | Institute of Cancer Research, United Kingdom | 2015-05-11 |
| Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer (NCT02863146) | Centre Oscar Lambret | 2015-05-01 |
| Observation of Medical Treatments in MBC HER2-negative Patients (NCT02365831) | Consorzio Oncotech | 2015-05-01 |
| Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis (NCT02422641) | Wake Forest University Health Sciences | 2015-05-01 |
| Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer (NCT02390427) | Otto Metzger, MD | 2015-04-20 |
| Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens (NCT02418689) | Hanmi Pharmaceutical Company Limited | 2015-04-01 |
| Real-World Outcome Research Study on Quality of Life, Work Productivity and Health Care Resource Utilization in Metastatic Breast Cancer (NCT02315365) | PeriPharm | 2015-03-01 |
| Patterns of Prescribing and Monitoring of Palbociclib (NCT03285568) | Rush University Medical Center | 2015-02-03 |
| Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D) (NCT02186015) | Loyola University | 2015-02-01 |
| A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors (NCT02322853) | Centre Francois Baclesse | 2015-01-01 |